

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

### How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

### What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

### What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

### Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

### What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email [gram.formularyteam@nhs.scot](mailto:gram.formularyteam@nhs.scot).

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](https://www.FreeDigitalPhotos.net)

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

NHS Grampian New Medicines Decisions – Formulary Group decisions 21 June 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
abrocitinib 50mg, 100mg, 200mg film-coated tablets (Cibinqo®)	<a href="#">2431</a>	For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. <b>SMC restriction:</b> for use in patients who have not responded to, or have lost response to, at least one systemic immunosuppressant therapy, or in whom these are contraindicated or not tolerated.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/06/2022
brigatinib 30mg, 90mg, 180mg film-coated tablets (Alunbrig®)	<a href="#">2314</a>	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.	Not routinely available as there is a local preference for alternative medicines	21/06/2022
cabozantinib 20mg, 40mg, 60mg film-coated tablets (Cabometyx®)	<a href="#">2386</a>	In combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults.	Not routinely available as there is a local preference for alternative medicines	21/06/2022
Descovy® 200mg/25mg film coated tablets (emtricitabine/tenofovir alafenamide fumarate)		In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk men who have sex with men, including adolescents (with body weight at least 35kg). <b>Restriction:</b> second-line choice in adolescents and adult men from 16 years of age, who: - are unable to take emtricitabine/tenofovir disoproxil (due to contraindication or intolerance), and - meet pre-exposure prophylaxis (PrEP) eligibility criteria	Routinely available in line with local guidance	21/06/2022

NHS Grampian New Medicines Decisions – Formulary Group decisions 21 June 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
dostarlimab 500mg concentrate for solution for infusion (Jemperli®)	<a href="#">2404</a>	As monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.	Routinely available in line with national guidance, on an interim basis subject to ongoing evaluation and future reassessment SMC 2404 <a href="https://www.scottishmedicines.org.uk/media/6727/dostarlimab-jemperli-final-december-2021-for-website.pdf">https://www.scottishmedicines.org.uk/media/6727/dostarlimab-jemperli-final-december-2021-for-website.pdf</a>	21/06/2022
enzalutamide 40mg film-coated tablets (Xtandi®)	<a href="#">2400</a>	Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).	Routinely available in line with national guidance, SMC 2400 <a href="https://www.scottishmedicines.org.uk/media/6666/enzalutamide-xtandi-final-jan-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/6666/enzalutamide-xtandi-final-jan-2022-for-website.pdf</a>	21/06/2022
fampridine 10mg prolonged-release tablets (Fampyra®)	<a href="#">2253</a>	For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7).	Routinely available in line with national guidance, SMC 2253 <a href="https://www.scottishmedicines.org.uk/media/5165/fampridine-fampyra-final-march-2020-for-website.pdf">https://www.scottishmedicines.org.uk/media/5165/fampridine-fampyra-final-march-2020-for-website.pdf</a>	21/06/2022
ixekizumab 80mg solution for injection in pre-filled syringe or pen (Taltz®)	<a href="#">2440</a>	Treatment of adult patients with: - active ankylosing spondylitis who have responded inadequately to conventional therapy - active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)	Not routinely available as not recommended for use in NHS Scotland, SMC 2440 <a href="https://www.scottishmedicines.org.uk/media/6932/ixekizumab-taltz-final-may-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/6932/ixekizumab-taltz-final-may-2022-for-website.pdf</a>	21/06/2022
lenvatinib 4mg, 10mg hard capsules (Kisplyx®)	<a href="#">2199</a>	In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.	Not routinely available as there is a local preference for alternative medicines	21/06/2022

NHS Grampian New Medicines Decisions – Formulary Group decisions 21 June 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
lenvatinib 4mg, 10mg hard capsules (Kisplicx®)	<a href="#">2476</a>	Treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line treatment. <b>SMC restriction:</b> treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/06/2022
melatonin 2mg MR tablets		[Off-label use] Second-line treatment in conjunction with other therapies and/or behavioural strategies, in children over 3 years of age and adults with learning difficulties with neuro-developmental disorders (including ADHD), autism spectrum disorders (ASDs), visual impairment, or other neuropsychiatric disorders, and chronic sleep disturbance where: - sleep hygiene measures have not been effective - symptoms of sleep disturbance have been present for at least six months - sleep disturbance is associated with significant interference with daily functioning	Routinely available in line with local guidance	21/06/2022
melatonin 2mg prolonged-release tablets (Circadin®)		[Off-label use] Second-line treatment in conjunction with other therapies and/or behavioural strategies, in children over 3 years of age and adults with learning difficulties with neuro-developmental disorders (including ADHD), autism spectrum disorders (ASDs), visual impairment, or other neuropsychiatric disorders, and chronic sleep disturbance where: - sleep hygiene measures have not been effective - symptoms of sleep disturbance have been present for at least six months - sleep disturbance is associated with significant interference with daily functioning	Not routinely available as there is a local preference for alternative medicines	21/06/2022

NHS Grampian New Medicines Decisions – Formulary Group decisions 21 June 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
miconazole nitrate 2% w/w cream		For the topical treatment of mycotic infections of the skin and nails and superinfections due to Gram-positive bacteria. First-line topical treatment for proven nipple candidiasis.	Routinely available in line with local guidance	21/06/2022
miconazole nitrate/ hydrocortisone 2%/1% w/w cream, ointment		For the topical treatment of inflamed dermatoses where infection by susceptible organisms and inflammation co-exist, e.g., intertrigo and infected eczema.	Routinely available in line with local guidance	21/06/2022
naldemedine 200micrograms film-coated tablets (Rizmoic®)		For the treatment of refractory opioid-induced constipation in adults with chronic non-cancer pain whose constipation has not adequately responded to at least two laxatives.	Routinely available in line with local guidance	21/06/2022
naldemedine 200micrograms film-coated tablets (Rizmoic®)		For the treatment of refractory opioid-induced constipation in adults with chronic cancer pain whose constipation has not adequately responded to at least two laxatives.	Routinely available in line with local guidance	21/06/2022
naloxegol 12.5mg, 25mg film-coated tablets (Moventig®)		For the treatment of refractory opioid-induced constipation in adults with chronic non-cancer pain whose constipation has not adequately responded to at least two laxatives.	Routinely available in line with local guidance	21/06/2022
naloxegol 12.5mg, 25mg film-coated tablets (Moventig®)		For the treatment of refractory opioid-induced constipation in adults with chronic cancer pain whose constipation has not adequately responded to at least two laxatives.	Routinely available in line with local guidance	21/06/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
oritavancin 400mg powder for concentrate for solution for infusion (Tenkasi®)	<a href="#">2285</a>	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. <b>SMC restriction:</b> patients with confirmed or suspected methicillin-resistant Staphylococcus aureus (MRSA) infection who are eligible for early discharge. Use should be on the advice of local microbiologists or specialists in infectious disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time	21/06/2022
ruxolitinib 5mg, 10mg, 15mg, 20mg tablets (Jakavi®)	<a href="#">2498</a>	For the treatment of patients aged 12 years and older with: - acute graft versus host disease who have inadequate response to corticosteroids - chronic graft versus host disease who have inadequate response to corticosteroids	Not routinely available as not recommended for use in NHS Scotland, SMC 2498 <a href="https://www.scottishmedicines.org.uk/media/6929/ruxolitinib-jakavi-non-sub-final-may-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/6929/ruxolitinib-jakavi-non-sub-final-may-2022-for-website.pdf</a>	21/06/2022
Ryeqo® 40mg/1mg/0.5mg film-coated tablets (relugolix/ estradiol/ norethisterone acetate)	<a href="#">2442</a>	Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. <b>SMC restriction:</b> for use in patients who have failed or are unsuitable for conventional therapies (first line treatments), such as tranexamic acid, hormonal contraceptives and intrauterine delivery systems.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/06/2022
tepotinib 225mg film-coated tablets (Tepmetko®)	<a href="#">2457</a>	For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.	Not routinely available as not recommended for use in NHS Scotland, SMC 2457 <a href="https://www.scottishmedicines.org.uk/media/6953/tepotinib-tepmetko-final-may-2022-amended-230622-for-website.pdf">https://www.scottishmedicines.org.uk/media/6953/tepotinib-tepmetko-final-may-2022-amended-230622-for-website.pdf</a>	21/06/2022

NHS Grampian New Medicines Decisions – Formulary Group decisions 21 June 2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
trametinib 0.5mg, 2mg film-coated tablets (Mekinist®)	<a href="#">2328</a>	In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. <b>SMC restriction:</b> after first line treatment.	Not routinely available as there is a local preference for alternative medicines	21/06/2022
zoledronic acid (monohydrate) 5mg/100mL solution for infusion	492/20	[Off-label use] For the treatment of osteoporosis in adults with a recent low trauma hip fracture.	Routinely available in line with local guidance	21/06/2022